NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Biotechnology: Saving Lives & Transforming Healthcare in the 21st Century
Modern biotechnology is a young industry. But in just a few decades, the entrepreneurs, scientists, researchers and investors working in this field have firmly established themselves at the forefront of medical innovation. Their work is transforming the way we treat –...
Sutro Appoints Lobacki as Director; Leonard, Krishnan & Levy as Advisors
SOUTH SAN FRANCISCO, April 27, 2017 –Sutro Biopharma Inc. is adding an expert in drug commercialization to its board of directors, appointing clinical and scientific advisors and promoting a key executive as it moves closer to clinical development of STRO-001, an...
American Association for Cancer Research (AACR) 2017 – Poster
Characterization and pre-clinical development of STRO-001, a novel CD74-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies 2017 combined MM and NHL AACR FINAL
Sutro ADC Targeting CD74 Eradicates B-Cell Hematologic Malignancy, Prolongs Survival in Tumor Models
SOUTH SAN FRANCISCO, April 3, 2017 – STRO-001, an antibody drug conjugate developed by Sutro Biopharma Inc., demonstrated potent anti-tumor activity in multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma tumor models while reducing the potential...
SutroVax Announces Closing of $64M via Series B Financing
Foster City, CA, March 21, 2017 – SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases, today announced the closing of a $60 million Series B...
Sutro ADC Targeting CD74 Exhibits Potent Anti-tumor Activity in Multiple Malignant Cell Lines and Animal Models of Non-Hodgkin Lymphoma and Multiple Myeloma
SOUTH SAN FRANCISCO, December 6, 2016 – Sutro Biopharma Inc. today announced that it has launched IND-enabling studies, including preparation for GLP toxicology, of STRO-001, an antibody drug conjugate, or ADC, that targets CD74, a protein highly expressed in B-cell...
American Society of Hematology (ASH) 2016 – NHL Oral Presentation
Targeting CD74 with Novel Antibody Drug Conjugates (ADCs) for the Treatment of B-Cell Non-Hodgkin’s Lymphoma Arturo Molina, MD, MS Sutro Biopharma ASH Annual Meeting 2016 ASH NHL Oral Presentation_120316 SLM
American Society of Hematology (ASH) 2016 – Poster
Discovery and preclinical development of novel CD74-targeting antibody-drug conjugates (ADCs) with significant activity in multiple myeloma (MM) cell lines and xenograft models 2016 DEC ASH MM Poster final no logo
BioTech Nation Radio with CEO Bill Newell
NPR and BioTech Nation interview Sutro's CEO William Newell to learn more about the next generation of cancer therapeutics. Click here to listen to the conversation as Bill describes Sutro's discovery and development efforts combining targeted warheads and ADC's in...
Sutro ADCs Targeting CD74 Suppress Tumors in Multiple Malignant Cell Lines and Animal Models of Multiple Myeloma and Non-Hodgkin Lymphoma
SAN FRANCISCO, Sept. 19, 2016 -- Sutro Biopharma Inc. today announced that it has presented findings from two studies of investigational antibody drug conjugates, or ADCs, that it developed to target CD74, a protein highly expressed in hematologic malignancies. The...